Shanghai Haohai Biological Technology Co., Ltd. convened its Board on 24 Apr 2026 and approved resolutions to expand and refresh the Board ahead of the 2025 Annual General Meeting (AGM). All appointments remain subject to shareholder approval at the AGM.

Executive Director nomination • Ms. Tian Min, currently Board Secretary and joint Company Secretary, is proposed as an additional Executive Director. • Tenure: from AGM approval to the end of the Sixth Board Session. • Profile highlights: joined Haohai in 2015; holds a PRC legal qualification (2014) and an SSE board-secretary certificate (2019); master’s degree in law from East China University of Political Science and Law; owns 10,189 A-shares of the Company.

Independent Non-Executive Director transition • In line with PRC regulations that cap INED service at six consecutive years, incumbents Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe have tendered resignations, effective upon the election of their successors. • Nominees to replace them are: – Mr. Chan Sui Yu, senior advisor at PwC Asset Appraisal (Shanghai); member of HKICPA and fellow of ACCA and RICS; Chinese Certified Public Valuer. – Mr. Song Yuanyang, professor and former Vice Dean, School of Business, East China University of Science and Technology; specialist in corporate strategy and international business. – Ms. Xu Duoqi, professor of law at Fudan University; director of the university’s Research Center for Digital Economy Rule of Law; multiple current independent directorships on PRC listed companies. • Each nominee has confirmed independence under Hong Kong Listing Rule 3.13.

Committee changes Upon appointment: • Mr. Chan will chair the Nomination Committee and join the Audit and Remuneration & Appraisal Committees. • Mr. Song will chair the Remuneration & Appraisal Committee and sit on the Audit and Nomination Committees. • Ms. Xu will join the Audit and Strategy & Sustainable Development Committees.

Next steps A circular detailing the proposed elections will be sent to shareholders. Remuneration for the new directors will follow the Company’s 2026 director compensation plan, subject to shareholder approval.

The outgoing INEDs have confirmed no disagreements with the Board and will remain in their roles until the new appointments take effect.